New approach to leukemia testing may better define prognosis, treatment

March 29, 2014
Pictured are Dr. Amyn Rojiani, Chairman of the MCG Department of Pathology (left) and Dr. Ravindra Kolhe, molecular pathologist at the Medical College of Georgia at Georgia Regents University. Credit: Phil Jones

Nearly half of patients with the most common form of adult leukemia are said to have normal chromosomes but appear instead to have a distinct pattern of genetic abnormalities that could better define their prognosis and treatment, researchers report.

Using that probes millions of genes within chromosomes, researchers found the unique pattern in the of 22 diagnosed with cytogenetically normal acute myelogenous leukemia, said Dr. Ravindra Kolhe, molecular pathologist at the Medical College of Georgia at Georgia Regents University.

"This is a total game changer," Kolhe said. "We have to use more sensitive tests to give patients the proper answer."

Kolhe, Director of the Georgia Esoteric, Molecular Labs, LLC, Department of Pathology, presented the findings March 29 during the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting in Nashville.

Acute myelogenous leukemia, the most common type of in adults, has about 20 subtypes, according to the National Cancer Institute. Patients with cytogenetically normal experience widely varying outcomes following chemotherapy and transplants. Ideally, identifying the causative genes will lead to a more targeted therapy and definitive prognosis, Kolhe said.

"The technology we currently use can't identify specifically what's wrong," Kolhe said. Patients have high percentages of cancer-producing cells called blasts in their blood and bone marrow but they do not show the distinctive chromosomal alterations that typically help characterize the leukemia and strategize therapy.

Genetic abnormalities, inherited and/or caused by environmental exposures – including previous chemotherapy and radiation treatment – are thought to cause leukemia. The result is that a disproportionate number of stem cells get stuck in the blast, or cancerous, stage, rather than maturing to that actually fight cancer and other invaders.

Patients often feel tired and feverish and blood tests reveal high blast levels. Pathologists then take about 20 leukemia cells, chemically block their constant division, open the nucleus, and spread the chromosomes on a slide. They examine the chromosomes with a microscope and in-situ hybridization technology, which helps detect small deletions or rearrangements.

"(Cytogenetically normal patients) show a normal chromosomal picture but they are clearly sick," Kolhe said. Frustrated at being unable to give these patients better information, he partnered with California-based Affymetrix to look directly at the genes within chromosomes using CytoScanHD microarray technology.

When he put cell contents instead on a computer chip with 2.7 million genetic probes, small, previously undetectable changes in the DNA became apparent in patients who had been classified as cytogenetically normal. In fact, every patient who looked normal under the microscope showed a consistent pattern. "It's the same finding in all 22 patients," Kolhe said.

He's continuing to collect patient data and is replicating the same genetic defects in mice to confirm that they cause .

Microarray technology is a research tool now finding a clinical presence. In January, Affymetrix received approval from the Food and Drug Administration to use its CytoScan® DX Assay to help diagnose developmental and intellectual disabilities in children.

Starting this summer, the Georgia Esoteric, Molecular Labs LLC at MCG will use this state-of-the-art technology to identify genetic disorders in children, while continuing to advance understanding of similar applications in cancer, said Dr. Amyn Rojiani, Chairman of the MCG Department of Pathology.

Explore further: New test enables early diagnosis of liver cancer

Related Stories

New test enables early diagnosis of liver cancer

September 19, 2013
Researchers have found a way to make early liver cancer show its true colors. They have developed a test that will help pathologists clearly distinguish early liver cancer cells from nearly identical normal liver cells by ...

Rare form of leukemia found to originate in stem cells

February 13, 2014
(Medical Xpress)—An international team of researchers working out of the University of Toronto has found that one type of rare leukemia appears to get its start in stem cells. In their paper published in the journal Nature, ...

FDA approves Pfizer drug for rare blood cancer

September 4, 2012
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.

Using cancer's fingerprint, researchers clinch a diagnosis

March 5, 2014
Rochester scientists are using a gene test to diagnose a difficult-to-detect form of bone marrow cancer – an example of how academic medical centers are applying new technology in ways that play to their strengths to achieve ...

Common mutation is culprit in acute leukemia relapse

March 6, 2014
Harvard stem cell scientists have identified a mutation in human cases of acute lymphoblastic leukemia that likely drives relapse. The research, published in Cancer Cell, could translate into improved patient care strategies ...

Major breakthrough in developing new cancer drugs: Capturing leukemic stem cells

March 18, 2014
The Institute for Research in Immunology and Cancer (IRIC) at the Université de Montréal (UdeM), in collaboration with the Maisonneuve-Rosemont Hospital's Quebec Leukemia Cell Bank, recently achieved a significant breakthrough ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.